Report: NovaQuest looking to sell NC-based ClinicalInk; RTI is an investor

RALEIGH – Investment firm NovaQuest is looking to sell Winston-Salem based ClinicalInk, which it acquired a majority interest in two years ago.

RTI International, which is based in RTP, was an investor in the Clinical Ink deal. Clinical Ink focuses on technology to reduce the cost of clinical trials.

PrivateEquity Hub reported late Thursday that NovaQuest was looking to sell the firm after pulling back from plans to do so earlier this year due to the COVID-19 pandemic. The news site cited four unnamed sources.

The companies delined comment.

Clinical Ink launched in 2007. The company says it provides software and solutions “purpose-built to capture data electronically at the point of care.” Its lead product, SureSource, “dramatically reduces development costs and timelines from Start to Submit.” the company says.

Formed in 2000, NovaQuest manages over $1.6 billion through biopharmaceutical investments and private equity deals.